Emma C. Rossi, MD

PARP inhibitors: New developments in ovarian cancer treatment

Publish date: June 5, 2017

Maturing data from ongoing trials will likely expand the opportunity to use PARP inhibitors for the treatment of ovarian cancer.

Publish date: May 3, 2017

High-quality surveillance care requires vigilance in the detection of recurrence, but also in the avoidance of unnecessary, costly, and inaccurate...

Publish date: February 3, 2017

The average lifetime risk of developing ovarian cancer is low, approximately 1 in 70. Even a clinical test with 100% sensitivity and 99%...

Publish date: October 3, 2016

The sentinel lymph node technique strikes a balance between the risks and benefits of lymph node evaluation in endometrial cancer.